中原內配:上半年新能源車配套氣缸套產品銷量表現較好
格隆匯7月18日丨中原內配(002448.SZ)今日披露的投資者關係活動記錄表顯示,新能源車領域是公司乘用車氣缸套產品的新增長點,伴隨着混合動力和增程式新能源車市場銷量的上升,2023年上半年公司為新能源車配套的氣缸套產品銷量表現較好,以理想汽車為代表的增程式發動機市場以及以比亞迪汽車為代表的混合動力發動機市場均有明顯突破。公司在南京建成氫能研發中心,目前已具備空壓機的設計、仿真、試製、測試、應用、分析等能力,獲得多項授權專利。公司研發的空壓機目前正在送樣測試階段,空壓機手工裝配線和電機試製線已經完成建設,年產5萬台的空壓機生產線建設中,預計2023年10月底前完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.